Countervail Corporation

Home
About Us
Technologies
Investors
Contact Us
News

Safeguarding Our Future

January 11, 2016 • admin •

Helping to prevent neurological damage from pesticide poisoning.

Related News

Countervail’s principal investigator presents at 2009 NINDS CounterACT meeting in Washington, DC. Dr. Edson Albuquerque presents additional data on galantamine’s effectiveness in preserving survival and prevention of neural cell damage from nerve agent exposure.

April 14, 2009

Canadian parent patent and CIP for the use of galantamine as a Method of Treating Organophosphorus Poisoning awarded.

October 27, 2015

Search for:

Latest News

Market Analysis Study for Countervail’s Novel Diagnostic Test Technology
New Countervail Corporation Patent Issued by USPTO
Countervail Awarded $225,000 SBIR Phase I Grant For Diagnostic Test Development
Preclinical Toxicology Study Shows Excellent Results On Countervail’s Lead Antidote Candidate
Data from two relevant animal models presented at the 2017 CounterACT meeting by Countervail CEO

Archives

Countervail Corporation's mission is to provide a layer of protection against the pesticides, chemical agents and other dangerous elements that threaten public safety.

By developing technologies and drugs that serve as counter agents, Countervail leads the way in making our world a better place.

Latest News

Market Analysis Study for Countervail’s Novel Diagnostic Test Technology
New Countervail Corporation Patent Issued by USPTO
Countervail Awarded $225,000 SBIR Phase I Grant For Diagnostic Test Development
Preclinical Toxicology Study Shows Excellent Results On Countervail’s Lead Antidote Candidate
Data from two relevant animal models presented at the 2017 CounterACT meeting by Countervail CEO

Looking For Something?

Search for:

© 2019 Countervail Corporation • Powered by Red Cape Design